Innovent Biologics Turns to H1 Profit

MT Newswires Live

Aug 27

Innovent Biologics (HKG:1801) recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.

Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.

Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.

The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.

The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562746204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562746204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562746204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-27 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562746204","market":"sg","top_or_hot":-1,"title":"Innovent Biologics Turns to H1 Profit","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> (HKG:1801) recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.</p><p>Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.</p><p>Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.</p><p>The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.</p><p>The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Turns to H1 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Turns to H1 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-27 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> (HKG:1801) recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.</p><p>Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.</p><p>Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.</p><p>The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.</p><p>The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562746204","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562746204","pubTimestamp":1756297572,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innovent Biologics  recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1583":"高瓴概念"},"translate_title":"信达生物上半年实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9},"content_text":"Innovent Biologics (HKG:1801) recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}